This is the one that would have completely removed the process for amending schedule 1 to CAMR, the access to medicines regime. It would collapse schedules 2 to 4, the lists of countries, into one list, without any additional requirements or parameters around those lists.
So what it would mean is that a number of fairly well-developed countries would be eligible for exports of drugs under this proposed bill. Countries like Mexico, Singapore, Brazil, and China, which might or do otherwise have pharmaceutical manufacturing capacity, would be eligible to receive medicines under this regime.